• Institution: LOCKSS
LOCKSS

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 3
Figure 3

IFN-α/β-inducible genes in WB of SLE patients can be used to separate SLE patients with IFN-α/β-inducible gene signature from healthy normal controls. (a) Three-dimensional PCA plot of WB from 41 SLE patients in the initial study using the 110 upregulated IFN-α/β-inducible transcripts upregulated in WB of SLE patients compared with those from 24 healthy donors. (b) PCA plot of WB from 54 SLE patients in the prospective study using the same 110 upregulated IFN-α/β-inducible transcripts confirmed the overexpression of IFN-α/β-inducible gene signatures in SLE patients. (c) PCA plot of WB from 95 SLE samples in both discovery and prospective study using the 21 upregulated IFN-α/β-inducible gene panel in SLE patients compared with 24 healthy donors. Each point represents one sample (blue points: healthy normal controls; red points: SLE patients). IFN = interferon; PCA = principal components analysis; SLE = systemic lupus erythematosus.

This Article

  1. Hum Genomics Proteomics vol. 1 no. 1